Johnson & Johnson (NYSE:JNJ)’s share price reached a new 52-week high during trading on Monday . The company traded as high as $123.45 and last traded at $123.31, with a volume of 2,392,636 shares. The stock had previously closed at $122.85.

JNJ has been the subject of a number of recent analyst reports. Goldman Sachs Group Inc. raised shares of Johnson & Johnson from a “sell” rating to a “neutral” rating and lifted their price target for the stock from $102.00 to $112.00 in a research note on Monday, March 14th. Jefferies Group reissued a “hold” rating and issued a $99.00 price objective (up from $92.00) on shares of Johnson & Johnson in a research report on Tuesday, March 15th. Piper Jaffray Cos. reissued an “overweight” rating and issued a $105.00 price objective on shares of Johnson & Johnson in a research report on Sunday, March 20th. Societe Generale assumed coverage on shares of Johnson & Johnson in a research report on Wednesday, April 6th. They issued a “hold” rating and a $113.00 price objective for the company. Finally, Wells Fargo & Co. reissued a “buy” rating and issued a $115.00 price objective on shares of Johnson & Johnson in a research report on Thursday, April 7th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have given a buy rating to the stock. Johnson & Johnson currently has an average rating of “Hold” and a consensus price target of $112.59.

The company’s 50 day moving average is $116.60 and its 200-day moving average is $108.93. The firm has a market cap of $338.96 billion and a price-to-earnings ratio of 22.46.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 19th. The company reported $1.68 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.65 by $0.03. The business earned $17.50 billion during the quarter, compared to analysts’ expectations of $17.50 billion. During the same period in the previous year, the business posted $1.56 EPS. The company’s revenue for the quarter was up .6% compared to the same quarter last year. On average, analysts predict that Johnson & Johnson will post $6.61 earnings per share for the current fiscal year.

In related news, CAO Ronald A. Kapusta sold 3,957 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, May 10th. The shares were sold at an average price of $114.77, for a total value of $454,144.89. Following the completion of the transaction, the chief accounting officer now owns 29,682 shares in the company, valued at $3,406,603.14. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Gary J. Pruden sold 9,735 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, June 7th. The stock was sold at an average price of $116.03, for a total transaction of $1,129,552.05. Following the completion of the transaction, the vice president now owns 43,630 shares of the company’s stock, valued at approximately $5,062,388.90. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have recently modified their holdings of the company. World Asset Management Inc increased its position in shares of Johnson & Johnson by 3.5% in the fourth quarter. World Asset Management Inc now owns 307,991 shares of the company’s stock worth $31,637,000 after buying an additional 10,434 shares in the last quarter. San Francisco Sentry Investment Group CA boosted its stake in Johnson & Johnson by 4.8% in the fourth quarter. San Francisco Sentry Investment Group CA now owns 18,551 shares of the company’s stock worth $1,906,000 after buying an additional 842 shares during the last quarter. Clean Yield Group boosted its stake in Johnson & Johnson by 3.2% in the fourth quarter. Clean Yield Group now owns 58,316 shares of the company’s stock worth $5,760,000 after buying an additional 1,800 shares during the last quarter. MU Investments Co. Ltd. boosted its stake in Johnson & Johnson by 570.8% in the fourth quarter. MU Investments Co. Ltd. now owns 45,950 shares of the company’s stock worth $4,743,000 after buying an additional 39,100 shares during the last quarter. Finally, Spinnaker Trust boosted its stake in Johnson & Johnson by 0.5% in the fourth quarter. Spinnaker Trust now owns 79,412 shares of the company’s stock worth $8,157,000 after buying an additional 373 shares during the last quarter.

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.